PAOLI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.653
EU - Europa 1.529
AS - Asia 955
SA - Sud America 85
Continente sconosciuto - Info sul continente non disponibili 64
AF - Africa 33
OC - Oceania 7
Totale 5.326
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.595
IT - Italia 545
RU - Federazione Russa 494
SG - Singapore 263
CN - Cina 248
HK - Hong Kong 156
IE - Irlanda 95
SE - Svezia 80
VN - Vietnam 77
KR - Corea 69
BR - Brasile 62
FR - Francia 58
FI - Finlandia 52
DE - Germania 50
PL - Polonia 44
CA - Canada 38
JO - Giordania 33
BD - Bangladesh 30
GB - Regno Unito 27
CH - Svizzera 26
NL - Olanda 24
IN - India 23
ID - Indonesia 13
ES - Italia 12
TR - Turchia 9
MX - Messico 8
AR - Argentina 7
AU - Australia 7
JP - Giappone 7
CI - Costa d'Avorio 5
EC - Ecuador 5
NG - Nigeria 5
MA - Marocco 4
UA - Ucraina 4
AT - Austria 3
DZ - Algeria 3
IQ - Iraq 3
JM - Giamaica 3
KE - Kenya 3
MY - Malesia 3
PK - Pakistan 3
RO - Romania 3
VE - Venezuela 3
ZA - Sudafrica 3
BJ - Benin 2
CL - Cile 2
CO - Colombia 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ET - Etiopia 2
IR - Iran 2
MM - Myanmar 2
NO - Norvegia 2
PH - Filippine 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BS - Bahamas 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
DK - Danimarca 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
NP - Nepal 1
PE - Perù 1
PR - Porto Rico 1
PY - Paraguay 1
SN - Senegal 1
TW - Taiwan 1
Totale 5.264
Salva come PNG Salva come JPEG
Città #
Santa Clara 506
Ashburn 346
Fairfield 191
Singapore 191
Hong Kong 133
San Jose 101
Woodbridge 95
Milan 94
Chandler 93
Dublin 93
Seattle 84
Houston 74
Cambridge 73
Seoul 69
Florence 66
Wilmington 62
Beijing 49
Los Angeles 49
Hefei 44
Warsaw 44
Council Bluffs 40
Rome 39
Altamura 37
Dallas 30
Lawrence 30
Princeton 28
Bern 26
Helsinki 24
Ann Arbor 23
Buffalo 23
Ho Chi Minh City 23
Lauterbourg 23
Paris 22
New York 21
The Dalles 21
Chicago 19
Figino 18
Shanghai 17
Moscow 16
Munich 16
Atlanta 15
Clifton 15
Turku 15
Boston 14
London 14
Toronto 13
Boardman 12
Jakarta 12
Medford 12
Mumbai 11
Bremen 10
Da Nang 10
Hanoi 10
Naples 9
Kent 8
Redondo Beach 8
Waltham 8
Amsterdam 7
Melbourne 7
San Diego 7
São Paulo 7
Bergamo 6
Dearborn 6
Frankfurt am Main 6
Frosinone 6
Montreal 6
Tokyo 6
Abidjan 5
Abuja 5
Ankara 5
Denver 5
Lappeenranta 5
Latina 5
Turin 5
Barcelona 4
Biên Hòa 4
Brescia 4
Brooklyn 4
Cagliari 4
Chennai 4
Dong Ket 4
Düsseldorf 4
Falls Church 4
Modena 4
Monza 4
Napoli 4
Norwalk 4
Padua 4
Palermo 4
Phoenix 4
Pomigliano d'Arco 4
Siena 4
Tianjin 4
Amman 3
Andover 3
Bari 3
Bắc Ninh 3
Charleston 3
Chengdu 3
Faenza 3
Totale 3.345
Salva come PNG Salva come JPEG
Nome #
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 405
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 286
Sviluppo e gestione di studi clinici indipendenti di Fase I/II nelle Neoplasie Mieloproliferative Croniche 273
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 250
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 231
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 230
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 210
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 205
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 203
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 202
Kaposi Sarcoma in a patient treated with Ruxolitinib 202
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 202
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 198
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 198
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 193
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 192
Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms 191
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group 186
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 186
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 174
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 167
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 162
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 161
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs 156
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 147
Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency 116
Totale 5.326
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.197
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.197
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022123 0 0 0 4 3 7 5 20 11 6 22 45
2022/2023505 43 96 34 29 29 77 61 28 60 6 15 27
2023/2024233 12 20 24 21 17 24 5 68 6 13 12 11
2024/20251.472 49 115 79 237 374 244 38 108 44 57 66 61
2025/20261.564 172 187 122 93 177 57 208 73 93 115 62 205
2026/2027562 66 228 184 84 0 0 0 0 0 0 0 0
Totale 5.326